SCHEMBL22116703

SCHEMBL22116703

CCOc1ccc(S(=O)(=O)Nc2ccc(Cl)cc2C#Cc2cnc(C(=O)OC)cc2OC)c2ncccc12

nearest known ligand 0.89

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 10/20 0.89
SLC16A7 O60669 1/20 0.89
SLC16A8 O95907 1/20 0.89
HTR5A P47898 1/20 0.89
POLB P06746 4/20 0.57
OPRD1 P41143 1/20 0.51
HTR6 P50406 1/20 0.51
SLC6A3 Q01959 1/20 0.51
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
MAPT P10636 1/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
ALPL P05186 1/20 0.41
SLC40A1 Q9NP59 1/20 0.41
HTT P42858 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Msc-4381 SCHEMBL31019750 0.94 SLC16A3 (1.00) SLC16A3SLC16A7SLC16A8HTR5APOLB
Msc-4381 SCHEMBL22116621 0.94 SLC16A3 (1.00) SLC16A3SLC16A7SLC16A8HTR5APOLB
SCHEMBL22116778 0.88 SLC16A3 (0.90) SLC16A3SLC16A7SLC16A8HTR5APOLB
SCHEMBL30182486 0.87 SLC16A3 (0.77) SLC16A3SLC16A7SLC16A8HTR5APOLB
SCHEMBL24109639 0.87 SLC16A3 (0.77) SLC16A3SLC16A7SLC16A8HTR5APOLB
SCHEMBL22116838 0.86 SLC16A3 (0.76) SLC16A3SLC16A7SLC16A8HTR5APOLB
SCHEMBL22116501 0.85 SLC16A3 (0.84) SLC16A3SLC16A7SLC16A8HTR5APOLB
SCHEMBL30188226 0.85 SLC16A3 (1.00) SLC16A3SLC16A7SLC16A8HTR5APOLB
SCHEMBL22116679 0.85 SLC16A3 (1.00) SLC16A3SLC16A7SLC16A8HTR5APOLB
SCHEMBL22134858 0.84 SLC16A3 (0.73) SLC16A3SLC16A7SLC16A8HTR5APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12351570-B2 Disubstituted alkyne derivatives MERCK PATENT GMBH (DE) 2025-07-08 US disclosed
US-20230052586-A1 DISUBSTITUTED ALKYNE DERIVATIVES MERCK PATENT GMBH (DE) 2023-02-16 US disclosed
US-20230052586-A1 DISUBSTITUTED ALKYNE DERIVATIVES MERCK PATENT GMBH (DE) 2023-02-16 US disclosed
EP-3898588-B1 DISUBSTITUTED ALKYNE DERIVATIVES MERCK PATENT GMBH (DE) 2023-01-11 EP disclosed
EP-3898588-B1 DISUBSTITUTED ALKYNE DERIVATIVES MERCK PATENT GMBH (DE) 2023-01-11 EP disclosed
WO-2021249969-A1 COMBINATION PRODUCT FOR THE TREATMENT OF CANCER DISEASES MERCK PATENT GMBH (DE) 2021-12-16 WO disclosed
WO-2021249969-A1 COMBINATION PRODUCT FOR THE TREATMENT OF CANCER DISEASES MERCK PATENT GMBH (DE) 2021-12-16 WO disclosed
EP-3898588-A1 DISUBSTITUTED ALKYNE DERIVATIVES Merck Patent GmbH (DE) 2021-10-27 EP disclosed
WO-2020127960-A1 DISUBSTITUTED ALKYNE DERIVATIVES MERCK PATENT GMBH (DE) 2020-06-25 WO disclosed
WO-2020127960-A1 DISUBSTITUTED ALKYNE DERIVATIVES MERCK PATENT GMBH (DE) 2020-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12351570-B2 Disubstituted alkyne derivatives BRCA1, MYC, PCNA SLC16A3 3198/4885SLC16A7 3694/4885SLC16A8 3364/4885
US-20230052586-A1 DISUBSTITUTED ALKYNE DERIVATIVES BRCA1, MYC, PCNA SLC16A3 3198/4885SLC16A7 3694/4885SLC16A8 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.